Stem Cell Research | Montefiore Einstein

Eric E. Bouhassira

Read more about Eric E. Bouhassira

Eric E. Bouhassira

https://assets.montefioreeinstein.org/profiles/images/4981-eric-bouhassira.jpg

Faculty

Expert

First Name

Eric

Last Name

Bouhassira

Faculty ID

4981

Patient Type

Adult

Department

einstein-dept-cell-biology

einstein-dept-medicine

einstein-dept-oncology

eric.bouhassira@einsteinmed.edu

Phone

718-430-2188

Titles

Type

Academic

Department

Department of Cell Biology

Department Link

Rank

Professor

Tags

me-patientcare-cancer-clinical-gastrointestinal

me-patientcare-cancer-research-stem-cell-cancer-biology

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Division

Oncology & Hematology

Type

Academic

Department

Department of Oncology

Rank

Professor

Division

Hematology

Type

Administrative

Title

Ingeborg and Ira Leon Rennert Professor of Stem Cell Biology and Regenerative Medicine

Locations

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Ullmann Building

Room

903A

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Professional Interests

Dr. Eric E. Bouhassira joined the Albert Einstein College of Medicine in 1990. He began studying human embryonic stem cells in 2001. He is director of the medical school's Center for Human Embryonic Stem Cell Research and professor of medicine and of cell biology. Dr. Bouhassira's research focuses on developing hematopoietic (blood forming) stem cells that can differentiate into red blood cells, T cells, platelets, and all other cell types that comprise blood. This work could potentially aid patients needing transfusions and also save lives by expanding the immunology diversity of hematopoietic stem cells available for transplant. Dr. Bouhassira is also interested in epigentic regulation in the erythoid and hematopoeitic lineag with a focus on DNA replication and DNA methylation. Dr. Bouhassira received his B.S., M.S., and Ph.D. degrees from the Université Pierre et Marie Curie in Paris, France. Dr. Bouhassira also holds the Ingeborg and Ira Rennert Chair in Stem Cell Biology and Regenerative Medicine.
Current Clinical Protocols
<ol>
<li>In vitro red blood cell production</li>
<li>Feasibility pilot study of therapies for sickle cell disease and Thalassemia</li>
<li>Quartet sequencing and genome phasing</li>
</ol>

Research Areas

Pluripotent stem cells, erythroid differentiation, red blood cells, gene therapy, hemoglobinopathies, genome modification, TTP, hemophilia A

Specialties

Basic Science

Expert Tags

Stem Cell Research

Areas of Expertise

Bioinformatics

Embryonic stem cells

Gene therapy

Globin genes

Hematopoiesis

Red blood cells

Sickle cell anemia

Thalassemia

Transcriptional regulation

Expert Summary

Dr. Bouhassira’s work focuses on prompting human embryonic stem cells to develop into hematopoietic (blood-forming), as well as stem cells, and into red blood cells. This work could potentially help patients needing transfusions and save lives by expanding the production of customized cells that could be transplanted without risk of rejection. The cells produced by Dr. Bouhassira can also be used to deliver therapeutic proteins to the circulatory system. 
Dr. Bouhassira’s research also aims to find cures for sickle cell disease by developing novel gene therapy strategies.

Research Profile

https://einsteinmed.edu/faculty/4981/Eric-Bouhassira

CHAM Provider

Off

Professional Title

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/e1288fe1-a5ea-4552-864c-2f73ddd55…

Selected Publications

Complete bibliography: <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-size: 11.5pt; font-family: Helvetica, sans-serif; color: #212121;"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/14gVia2i54M5O/bibliography/public/"… style="font-size: 11.5pt; font-family: Helvetica, sans-serif; color: #4c2c92; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">https://www.ncbi.nlm.nih.gov/myncbi/14gVia2i54M5O/bibliography/public/<…;
Research areas:
Development of methods to produce cultured red blood cells from hematopoietic stem cells and from pluripotent stem cells.
Progress in cell culture methods has open up the possibility of manufacturing red blood cells (RBCs) for transfusion. We have developed methods to produce large number of red blood cells from hematopoietic stem cells and from pluripotent stem cells. Using detailed analysis of globin chain expression, we were the first to demonstrate that differentiation of hESCs and iPSCs into erythroid cells faithfully recapitulates the embryonic and fetal stages of human erythropoiesis but do not yield red blood cells with an adult phenotype. We also demonstrated that fetal stage erythroid cells derived from pluripotent cells can enucleate in vitro.Since these early studies, observations that cells produced from pluripotent cells are developmentally immature have been made in many other lineages, by others. Finding methods to produce developmentally mature cells from pluripotent stem cells has become a central focus of many labs including my own. We recently obtained NIH funding to apply our advanced culture methods and translate our results into a commercial product by developing a panel of IPSC lines from patients carrying very rare blood groups that can be used as universal donor for transfusion and as reagent RBCs that will be used to type antibodies in allo-immunized patients with sickle cell disease.
1.    Olivier EN, Qiu C, Velho M, Hirsch RE, Bouhassira EE. Large-scale production of embryonic red blood cells from human embryonic stem cells. Exp Hematol. 2006 Dec;34(12):1635-42. PMID: 17157159 Cited by 161 
2.    Qiu C, Olivier EN, Velho M, Bouhassira EE. Globin switches in yolk sac primitive and fetal definitive RBCs produced from human embryonic stem cells. Blood. 2008; 111(4):2400-8. PMID: 18024790 Cited by 154
3.    Wang K, Guzman AK, Yan Z, Zhang S, Hu MY, Hamaneh MB, Yu YK, Tolu S, Zhang J, Kanavy HE, Ye K, Bartholdy B, Bouhassira EE. Ultra-High-Frequency Reprogramming of Individual Long-Term Hematopoietic Stem Cells Yields Low Somatic Variant Induced Pluripotent Stem Cells. Cell Rep. 2019 Mar 5;26(10):2580-2592.e7  PMID: 30840883 Cited by 2
4.    Olivier EN, Zhang S, Yan Z, Suzuka S, Roberts K, Wang K, Bouhassira EE. RED, an Albumin-Free Robust Erythroid Differentiation Method to Produce Enucleated Red Blood Cells from Human Pluripotent and Adult Stem Cells. Exp Hematol. 2019 Jul;75:31-52.e15 PMID: 31176681
5.     Olivier EN, Wang K, Grossman J, Mahmud N, Bouhassira EE. Differentiation of Baboon (Papio anubis) Induced-Pluripotent Stem Cells into Enucleated Red Blood Cells. Cells. 2019 Oct 19;8(10).PMID: 31635069.
Gene therapy for the hemoglobinopathies
 Lentiviral based gene therapy for the hemoglobinopathies is coming of age. We have contributed to the field by studying at the basic science level the major causes of transgene silencing in erythroid cells. Using the RMCE method we have demonstrated that in eukaryotic cells, silencing is not primarily caused by integration near heterochromatin but rather by transcriptional interferences between the transgenes and neighboring sequences. By studying cassettes that were either devoid of any CpG dinucleotides, or that were pre-methylated prior to integration, we were able to demonstrate that DNA methylation is not necessary for silencing but that it confers an epigenetic memory.
We also demonstrated that inclusion of insulators in gene therapy cassettes was a double edged sword since these elements can prevent silencing and insertional mutagenesis at some genetic loci, but can also cause silencing and insertional mutagenesis at other locations. Some of these basic science findings were applied to design the gene therapy cassettes that were used, in collaboration with the Leboulch lab, to provide the first proof of principle in mice that gene therapy could be used to cure sickle cell disease. These vectors are currently tested by BlueBird therapeutics in human clinical trials that have had encouraging results.
1.    Feng YQ, Warin R, Li T, Olivier E, Besse A, Lobell A, Fu H, Lin CM, Aladjem MI, Bouhassira EE. (2005): The Human b-Globin Locus Control Region Can Silence as Well as Activate Gene Expression. Mol Cell Biol.25: (10):3864-74. PMID: 15870261 Cited by 44
2.    Feng YQ, Desprat R, Fu H, Olivier E, Lin CM, Lobell A, Gowda SN, Aladjem MI, Bouhassira EE. (2006). DNA methylation supports intrinsic epigenetic memory in mammalian cells. PLoS Genet. 2006 Epub 2006 Apr 28. PMID: 16683039 Cited by 75
3.    Pawliuk R., KA Westerman, ME Fabry, E Payen, R Tighe, EE Bouhassira, SA Acharya, J Ellis, IM London, CJ Eaves, RK Humphries, Y Beuzard, RL Nagel, P Leboulch  (2001):  Correction of sickle cell disease in transgenic mouse models by gene therapy. Science  294:2368-71. PMID: 11743206 Cited by 574 
4.    Boulad F, Maggio A, Xiuyan Wang X, Moi P, Acuto S, Kogel F, Takpradit A, Prockop S, Mansilla-Soto J, Cabriolu A, Odak A. Thummar K, Du F, Shen L, Raso s, Barone R, Di Maggio R, Pitrolo L, Giambona A, Mingoia M, Everett JK, Hokama P, Roche A, Cantu A, Adhikari H, Reddy S, Bouhassira EE, Mohandas N, Bushman FD, Rivière I, Sadelain M (2001) Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.  Nat Med. 2022 Jan;28(1):63-70.
Development of Recombinase-Mediated Cassette Exchange and safe harbor concept
Lentiviral transduction, stable transfection and transgenesis results in random integration of transgenes which leads to positive or negative position-effects. Position-effects greatly complicate gene therapy as well as the interpretation of most stable transfection or transduction experiments. To eliminate these problems, we have developed RMCE, a method that allows site-specific integration of cassettes at predetermined chromosomal locations in mammalian cells. We used the method extensively to better understand the molecular basis of position-effects in erythroid cells (see above). Many other labs, all over the world, have adopted RMCE, and adapted it to many cell types and many organisms. Over 500 studies that take advantage of RMCE have been published.
            The use of the RMCE led us to develop the concept of safe harbors as an efficient method to perform gene therapy safely and cost efficiently, without having to design and test novel vector or gene editing strategy for every mutation in every defective human gene. We demonstrated the concept by correcting alpha-thalassemia in iPSCs by targeting constructs to the AAVS1.
1.    Bouhassira EE., K Westerman, P Leboulch: (1997) Transcriptional Behavior Of LCR Elements Integrated At The Same Chromosomal Locus By RMCE. Blood, 90: 3332-3244. PMID: 9345015 Cited by 177
2.    Feng YQ, Seibler J, Alami R, Eisen A, Fiering SN, Bouhassira EE: (1999) Site-Specific Chromosomal Integration In Mammalian cells: Highly Efficient CRE Recombinase-Mediated Cassette Exchange. J. Mol. Biol. 292 (4): 779-785. PMID: 10525404 Cited by 249
3.     Chang CJ and Bouhassira EE. Zinc-finger nuclease mediated correction of α-thalassemia in iPS cells. Blood. 2012; Nov 8;120(19):3906-14. PMID: 23002118 Cited by 100
Molecular basis of Thrombotic Thrombocytopenic Purpura
In collaboration with Dr. Han-Mou Tsai we have demonstrated that ADAMTS13 is responsible for congenital TTP, that auto-antibody resistant forms of the protein could be generated, that ADMTS13 is expressed predominantly in stellate cells, and we have explored some of the molecular mechanisms associated with low levels of ADAMTS13 expression in human population. 
1.    Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413(6855):488-94. PMID: 11586351. Cited by 1683
2.    Zhou W, Dong L, Ginsburg D, Bouhassira EE, Tsai HM. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? The Journal of biological chemistry. 2005; 280(48):39934-41. PMID: 16203734   Cited by 59 
3.    Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta S, Tsai HM. ADAMTS13 is expressed in hepatic stellate cells. Laboratory investigation; a journal of technical methods and pathology. 2005; 85(6):780-8. PMID: 15806136  Cited by 162 
4.    Zhou W, Bouhassira EE, Tsai HM. An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers. Blood. 2007; 110(3):886-93. PMID: 17426255   Cited by 38
Characterization of replication timing and replication origins in human primary erythroid cells
Gene transcription is regulated by transcription factors and by chromatin structure. Using the Recombinase-Mediated Cassette Exchange (RMCE) method and b-globin transgenes as a model, we demonstrated that replication timing plays a critical role in gene expression at some genetic loci in erythroid cells. This prompted us to investigate the mechanisms that regulate replication timing in basophilic erythroblasts. In collaboration with the Schildkraut and Mieg labs, we developed the TimEX and TimEX-seq method to measure replication timing genome-wide using tiling micro-arrays and massively parallel sequencing. We applied these methods to generate genome-wide maps of replication timing in several cell types that demonstrated that replication timing is very tightly regulated in mammalian cells and that the timing of replication and gene expression levels are very closely linked. 
In collaboration with the Aladjem lab, we also developed methods to generate allele-specific profiles of replication timing and replication origins. Using these maps and a novel analytic approach, we show that the two chromosome homologs replicate within a few minutes of each other in about 92% of the genome but that about 8% of the genome replicate asynchronously. Asynchrony is associated with imprinting random mono-allelic expression and proximity to large structural variants. We also showed that an asymmetry in nucleotide distribution, which increases the propensity of origins to unwind and adopt non-B DNA structure, rather than the ability to form G4-quadruplexes, is directly associated with origin activity. This work also led to the development of GenPlay, a powerful, JAVA, open-source genome browser and analyzer application that is available online and currently utilized by over 100 labs worldwide.
1.    Fu H., Lixin W., Lin CH, Singhania S, Bouhassira EE, Aladjem MI. Human Replicators Can Prevent Gene Silencing. Nature Biotech.  2006, 24(5):572-6. PMID: 16604060 Cited by 37 
2.    Desprat R, Thierry-Mieg D, Lailler N, Lajugie J, Schildkraut C, Thierry-Mieg J, Bouhassira EE. Predictable dynamic program of timing of DNA replication in human cells. Genome Research. 2009 Dec;19(12):2288-99. PMID: 19767418 Cited by 117
3.    Mukhopadhyay R, Lajugie J, Fourel  N, Selzer A, Schizas M, Bartholdy B, Mar  J, Lin  CM, Martin MM , Ryan  M, Aladjem MI and Bouhassira EE. Allele-Specific Genome-wide Profiling in Human Primary Erythroblasts Reveal Replication Program Organization. PLoS Genet. 2014 May 1;10(5):e1004319.  PMID: 24787348  Cited by 42 
4.    Bartholdy B, Mukhopadhyay R, Lajugie J, Aladjem MI, Bouhassira EE. Allele-specific analysis of DNA replication origins in mammalian cells. Nat Commun. 2015 May 19;6:7051. PMID: 25987481 Cited by 32

Is Open Scheduling

Off

Sanjeev Gupta

Read more about Sanjeev Gupta

Sanjeev Gupta

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/320e3550-5d55-11ef-82d4-99c0ef58f445.jpg

Provider

Faculty

Expert

First Name

Sanjeev

Last Name

Gupta

NPI

1831274315

Faculty ID

8041

CMO Specialties

Gastroenterology

Cancer

Hepatology

Clinical Terms

Nonalcoholic Steatohepatitis

Postcholecystectomy Syndrome

Wilson Disease

Acute Liver Failure

Hepatitis A

Cholestatic Hepatitis

Biliary Atresia

Gallbladder Problems

Hepatic Encephalopathy

Primary Biliary Cholangitis

Employment Status

Full Time

Patient Type

Adult

Department

einstein-dept-medicine

einstein-dept-pathology

Gender

Male

sanjeev.gupta@einsteinmed.edu

Phone

718-430-3309

Titles

Type

Academic

Department

Department of Medicine

Department Link

Rank

Professor

Division

Hepatology

Type

Academic

Department

Department of Pathology

Department Link

Rank

Professor

Type

Administrative

Title

The Eleazar & Feige Reicher Chair in Translational Medicine, Department of Medicine

Tags

me-patientcare-cancer-research-stem-cell-cancer-biology

Locations

Is Primary

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.84154 40.84612)

Address Line 1

1250 Waters place

City

Bronx

State

Zip

10461-2720

Location Title

Montefiore at 1250 Waters Place

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Ullmann Building

Room

625

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Education and Trainings

Education Type Label

Medical Education

Education Institution

University of Rajasthan, Sardar Patel Med Coll

Education Type Label

Fellowship

Education Institution

Hammersmith Hospital

Education Type Label

Fellowship

Education Institution

Los Angeles County and Univ of Southern CA

Education Type Label

Fellowship

Education Institution

Jacobi Medical Center

Education Type Label

Residency

Education Institution

Jacobi Medical Center

Education Type Label

Residency

Education Institution

Postgraduate Institute of Medical Educ. & Research

Education Type Label

Residency

Education Institution

Hammersmith Hospital

Professional Interests

Liver regeneration is critical for health. We focus on physiology of liver regeneration during development, early childhood and adulthood to inform mechanistic disruptions in diseases. The latter ranges from acute liver failure, effects of drugs, toxins, alcohol, virus hepatitis, obesity-related metabolic (or nonalcoholic) liver disease, chronic hepatitis, e.g., Wilson disease with copper toxicosis, and allograft rejection. The mechanisms concerning DNA damage response directed by ATM gene and downstream partners are of considerable interest to us.     
These aspects are joined with study of cell type-specific contributions as well as aspects of stem cell biology for liver regeneration. We apply cell transplantation approaches to better understand the biology and regenerative potential of various cell types. Expression of therapeutic constructs and transplantation of those cells is another area of investigative interest. We address the role of endogenous stem/progenitor cells in therapeutic development. Tissue engineering to generate auxiliary liver has potential in these areas and is also advancing liver regenerartion in experimental models.
We use a variety of methods, including microarrays or deep sequencing for gene expression, cell and molecular biology methods, and multiple small and large animal models. The findings are integrated with analyses of human tissue and blood samples.
Unique aspects of our work include use of established drugs for mechanistic interrogations and therapeutic applications, and an uncommon depth and breadth of multidisciplinary tools. We collaborate with leading investigators at Einstein or elsewhere as appropriate.

Research Areas

Liver regeneration in health and disease
Biology and differentiation of hepatic stem cells
DNA damage response involving ATM and downstream pathways
Translational studies using liver cell and animal models
Therapeutics including cell and gene therapy

Expert Tags

Stem Cell Research

Liver Disease

Areas of Expertise

Stem cell research

Expert Summary

Dr. Gupta is a pioneer in the development of cell therapy – treating disease by introducing healthy cells into the body.  He has discovered various mechanisms for coaxing transplanted cells to attach to host tissue and multiply, paving the way for treating health problems such as  high cholesterol, hemophilia, liver failure, and hepatitis. 
Dr. Gupta has successfully manipulated human stem cells to generate liver cells and defined some of the fundamental ways by which gene expression is regulated in stem cells. Dr. Gupta serves as an expert for the National Institutes of Health, U.S. Department of Veterans Affairs, U.S. Department of Defense, Wellcome Trust, and national scientific bodies in over ten countries.
In the 1990s, Dr. Gupta contributed to the first ever clinical trial of a cell/gene therapy for familial hypercholesterolemia (high cholesterol), which results from a gene defect. He also showed that Wilson’s disease (a genetic condition characterized by excessive accumulation of copper in the liver and brain) could potentially be cured by use of cell therapy.

Research Profile

https://einsteinmed.edu/faculty/8041/Sanjeev-Gupta

Clinical Profile

https://montefioreeinstein.org/profiles/1831274315/sanjeev-gupta

CHAM Provider

Off

Professional Title

M.B.,B.S.

M.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/030dab4b-4f73-4a6e-af92-82cf0408d…

Selected Publications

<ul type="disc"></ul>
<ul type="disc">
<li>Thirunavukkarasu C, Sharma Y, Tchaikovskaya T, Maslov AY, Gupta S. Transcriptional profiling reveals ataxia telangiectasia mutated pathways regulate joint copper and arsenic toxicity for hepatic metalloplasia and anti-cancer therapies. Life Sci. 2022 Jul 6;120787. doi: 10.1016/j.lfs.2022.120787. </li>
<li>Chang CJ, Ge EJ Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, Dou Q, Franz KJ, Gohil VM, Gupta S, Kaler SG, Lutsenko S, Mittal V, Petris MJ, Polishchuk R, Ralle M, Schilsky ML, Tonks NK, Vahdat LK, Van Aelst L, Xi D, Yuan P, Brady DC. Connecting copper and cancer from transition metal signaling to metalloplasia in the clinic. Nat Rev Cancer 2022 Feb;22(2):102-113. doi: 10.1038/s41568-021-00417-2. Epub 2021 Nov 11. PMID: 34764459</li>
<li>Viswanathan P, Gupta P, Sharma Y, Maisuradze L, Bandi S, Gupta S. Caffeine disrupts ataxia telangiectasia mutated gene-related pathways and exacerbates acetaminophen toxicity in human fetal immortalized hepatocytes. Toxicology. 2021 May 7;457:152811. doi: 10.1016/j.tox.2021.152811. PMID: 33971260</li>
<li>Viswanathan P, Sharma Y, Jaber FL, Tchaikovskaya T, Gupta S. Transplanted hepatocytes rescue mice in acetaminophen-induced acute liver failure through paracrine signals for hepatic ATM and STAT3 pathways. FASEB J 2021 Apr;35(4):e21471. doi: 10.1096/fj.202002421R. PMID: 33683737</li>
<li>Jaber FL, Sharma Y, Mui BG, Kapoor S, Gupta S. Tumor necrosis factor directs allograft-related innate responses and its neutralization improves hepatocyte engraftment in rats. Am J Pathol 2021; 191(1):79-89. doi: 10.1016/j.ajpath.2020.09.014. Epub 2020 Oct 27. PMID: 33127336</li>
<li>Viswanathan P, Sharma Y, Gupta S. Ataxia telangiectasia mutated pathway disruption affects hepatic DNA and tissue damage in nonalcoholic fatty liver disease. Exp Mol Pathol. 2020 Apr; 113:104369. doi: 10.1016/j.yexmp.2020.104369. Epub 2020 Jan 7. PMID: 31917286</li>
<li>Gupta P, Sharma Y, Viswanathan P, Gupta S. Cellular receptor signaling and ATM pathway intersections regulate hepatic DNA repair. Cytokine 2020 Mar; 127:154946. doi: 10.1016/j.cyto.2019.154946. Epub 2019 Dec 11. PMID: 31837586</li>
<li>Bandi S, Tchaikovskaya T, Gupta S. Hepatic differentiation in human pluripotent stem cells by developmental stage-specific metabolomics products. Differentiation 2019; 105:54-70. Jan 28;105:54-70. doi: 10.1016/j.diff.2019.01.005. PMID: 30776728.</li>
<li>Kakabadze Z, Karalashvili L, Chakhunashvili D, Havlioglu N, Janelidze M, Kakabadze A, Sharma Y, Gupta S. Decellularized bovine placentome for portacavally-interposed heterotopic liver transplantation in rats. Mater Sci Eng C Mater Biol Appl. 2019 Apr; 97:293-301. doi: 10.1016/j.msec.2018.12.025. Epub 2018 Dec 10. PMID: 30678914.</li>
<li>Yadav N, Jaber FL, Sharma Y, Viswanathan P, Gupta S. Efficient reconstitution of hepatic microvasculature by endothelin receptor antagonism in liver sinusoidal endothelial cells. Hum Gene Ther 2018; Sep 28. doi: 10.1089/hum.2018.166. PMID: 30266073, </li>
<li>Sharma Y, Liu J, Kristian KE, Follenzi A, Gupta S. In Atp7b-/- mice modeling Wilson's disease liver repopulation with bone marrow-derived myofibroblasts or inflammatory cells and not hepatocytes is delterious. Gene Expr. 2018 Jul 20. doi: 10.3727/105221618X15320123457380. PMID: 30029699</li>
<li>Bandi S, Gupta S, Tchaikovskaya T, Gupta S. Differentiation in stem/progenitor cells along fetal or adult hepatic stages requires transcriptional regulators independently of oscillations in microRNA expression. Exp Cell Res. 2018 Sep 1;370(1):1-12. doi: 10.1016/j.yexcr.2018.06.004. Epub 2018 Jun 6.</li>
<li>Benten D, Kluwe J, Wirth JW, Thiele ND, Follenzi A, Bhargava KK, Palestro CJ, Koepke M, Tjandra R, Volz T, Lutgehetmann M, Gupta S. A humanized mouse model with liver fibrosis following expansion of transplanted hepatic stellate cells in injury and inflammation. Lab Invest 2018 Apr;98(4):525-536. doi: 10.1038/s41374-017-0010-7. Epub 2018 Jan 19.PMID: 29352225.</li>
<li>Viswanathan P, Sharma Y, Gupta P, Gupta S. Replicative stress and alterations in cell cycle checkpoint controls following acetaminophen hepatotoxicity restrict hepatic regeneration. Cell Prolif 2018; Jun;51(3):e12445. doi: 10.1111/cpr.12445. Epub 2018 Mar 5. PMID: 29504225.</li>
<li>Kakabadze Z, Kakabadze A, Chakhunashvili D, Karalashvili L, Berishvili E, Sharma Y, Gupta S. Decellularized human placenta supports hepatic tissue and allows rescue in acute liver failure. Hepatology 2018 May;67(5):1956-1969. PMID: 29211918. </li>
</ul>

EMR ID

3601

Is Open Scheduling

Off

Chandan Guha

Read more about Chandan Guha

Chandan Guha

https://assets.montefioreeinstein.org/profiles/images/physphoto/Guha_Chandan_MD_420x504.jpg

Provider

Faculty

Expert

First Name

Chandan

Last Name

Guha

NPI

1093917924

Faculty ID

7020

CMO Specialties

Radiation Oncology

Genitourinary (GU) Cancer

Cancer

Clinical Terms

Stereotactic Radiation Therapy

Radiosurgery

External Beam Radiation Therapy

Neutropenia

Radiation Therapy

Leukopenia

Employment Status

Full Time

Patient Type

Adult

Department

einstein-dept-radiation-oncology

einstein-dept-pathology

einstein-dept-urology

Gender

Male

cguha@montefiore.org

Phone

718-920-2702

Titles

Type

Academic

Department

Department of Radiation Oncology

Rank

Professor

Type

Academic

Department

Department of Pathology

Department Link

Rank

Professor

Type

Academic

Department

Department of Urology

Department Link

Rank

Professor

Type

Clinical

Title

Associate Director for Clinical/Translational Research, Institute for Immunotherapy

Tags

me-patientcare-cancer-research-immunotherapy

Type

Administrative

Title

Associate Director, Innovation/Tech Transfer, Montefiore Einstein Comprehensive Cancer Center

Tags

me-patientcare-cancer-about-associate-directors

me-patientcare-cancer-research-therapeutics

Type

Administrative

Title

Vice Chair, Department of Radiation Oncology

Tags

me-patientcare-cancer-clinical-gastrointestinal

me-patientcare-cancer-clinical-genitourinary-urologic

Type

Administrative

Title

The Harry Eagle Chair in Cancer Research/National Women's Division

Locations

Is Primary

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.84599 40.84617)

Address Line 1

1625 Poplar Street

City

Bronx

State

Zip

10462-2653

Location Title

Montefiore Medical Park at 1625 Poplar

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8459022 40.8504961)

Building

Block

Room

620

Address Line 1

Albert Einstein College of Medicine

Address Line 2

Jack and Pearl Resnick Campus

Address Line 3

1300 Morris Park Avenue

City

Bronx

State

Zip

10461

Location Title

Albert Einstein College of Medicine

Education and Trainings

Education Type Label

Medical Education

Education Institution

Calcutta University

Education Type Label

Residency

Education Institution

Montefiore Medical Center

Education Type Label

Residency

Education Institution

Washington University School of Medicine

Professional Interests

Exploring therapeutic potential of stem cell regeneration in the event of radiation insult Exposure to high doses of ionizing radiation in the event of therapeutic, accidental or intentional incident such as nuclear/radiological warfare can lead to debilitating injuries to multiple organs resulting in death within days depending on the amount of radiation dose and the quality of radiation. Unfortunately, there is not a single FDA-licensed drug approved against acute radiation injury.
Radiation damage to multiple organs often described as multiple organ dysfunction syndrome (MODS) or acute radiation syndrome (ARS) results from rapid depletion of radiosensitive cells, these cells are usually the stem or progenitor cells with high proliferative capacity; naturally, bone marrow stem cells (BMSC), and intestinal stem cells (ISC), which are extremely critical in maintaining a pool of peripheral blood cells and in maintaining villi for the absorption of nutrients are highly sensitive to radiation. One of the most efficient ways of rescuing MODS is to administer fresh cells that can repair, support and/or replace the damaged cells and repopulate the damaged tissue with healthy cells. The Rad-Stem Center for Medical Countermeasures against Radiation (RadStem CMCR) program at Einstein is developing stem cell-based therapies to treat acute radiation syndrome (ARS) that results from radiation injury.
Radiation-induced gastrointestinal syndrome (RIGS) results from a combination of direct damage to intestinal crypt and endothelial cells, and subsequent loss of the mucosal barrier leading to microbial infection, septic shock and systemic inflammatory response syndrome (SIRS). Currently, there is no treatment for RIGS in clinic. Irradiation induces apoptosis of crypt ISC, endothelial cells and enterocytes within hours. Acute loss of cells in situ requires rapid compensation of their functions and this is best achieved using cell replacement therapies. We are interested in exploring intestinal regenerative therapy with a combination of systemic administration of growth factors and cell replacement therapy to salvage Gl function post-radiation exposure. We are testing combinations of: a) intestinal stem cell growth factor, R-spondinl (R-spol), b) TLR ligands, and c) transplantation of bone marrow-derived endothelial progenitor cells (EPC) and mesenchymal stem cells (MSC) to restore IR-damaged ISC niche, protect against IR-induced cell death and provide growth signals for host ISC regeneration, thus providing protection and mitigation from RIGS.
Preparative live irradiation for hepatocyte transplant in acute liver injury and cirrhosis Hepatocyte transplantation (HT) is a very attractive alternative to liver transplant in the treatment of both inherited and acquired liver diseases. However, benefits of this procedure are currently limited by the inability of the transplanted hepatocytes to proliferate in the host liver, and lack of a noninvasive method to evaluate the repopulation of transplanted hepatocytes in the liver. In order to develop a clinically feasible protocol for HT, we are exploring preparative hepatic irradiation (HIR) for liver repopulation (in place of liver transplant) to deplete host hepatocytes and permit preferential proliferation of the engrafted donor cells in response to hepatic mitotic stimuli.  Our lab was the first one to demonstrate that preparative HIR and partial hepatectomy (PH), followed by HT results in the replacement of virtually all host hepatocytes by the transplanted non-irradiated hepatocytes in 12 weeks. We are interested in using inducible pluripotent stem cells (iPSC)- derived hepatocytes following highly focused irradiation of the damaged liver in place of a liver transplant. We are also interested in exploring non-invasive biomarkers to validate that the transplanted hepatocytes can efficiently replace host hepatocytes upon liver irradiation.
Cancer Immunotherapy Radiation therapy (RT) has been used as a standard treatment modality for many solid tumors. While tumoricidal properties of RT are instrumental for standard clinical application, irradiated tumors can potentially serve as a source of tumor antigens in vivo, where dying tumor cells would release various tumor antigens slowly over time. Using different in vitro and in vivo tumor models we, and others, demonstrated that RT enhances oxidative stress, and augments the release of necessary activating signals for DC such as endogenous danger associated molecular pattern (DAMP) molecules from irradiated cells. These RT-mediated processes lead to an increase antigenecity of irradiated cells which augments antigen presentation leading to an effective anti-tumoral immune responses. However the underlying mechanism of this processes has still to be determined.
Over the last years we have been interested in designing novel tumor vaccines that amplify the tumor immune response using conventional and exploratory cancer therapies. In particular we are focusing on evaluating the immunogenic properties of radiation therapies and determine how immunotherapeutic molecules can synergize with RT in boosting immune cells cell function. We are also interested in exploring therapeutic effect of ultrasound therapy in the treatment of solid tumor. Our recent work on use of Listeria-based vaccine therapy in combination of RT shows that this strategy is more effective than RT alone.

Specialties

Cancer

Expert Tags

Radiation Oncology

Stem Cell Research

Areas of Expertise

Targeted delivery of chemotherapy and immunotherapies for cancer

Cancer radiation treatment dosage and standards

Expert Summary

Dr. Guha is a radiation oncologist who specializes in prostate, genitourinary, liver and GI malignancies, and radio surgery. His research interests include development of stem-cell based therapies to treat radiation-induced toxicity and prevent death in patients.

Research Profile

https://einsteinmed.edu/faculty/7020/Chandan-Guha

Clinical Profile

https://montefioreeinstein.org/profiles/1093917924/chandan-guha

CHAM Provider

Off

Professional Title

M.B.,B.S.

Ph.D.

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/ce62a4da-414e-437a-a0ab-4eaf90df6…

Selected Publications

Immunomodulation of radiation therapy: Radiation-enhanced tumor vaccines
<ol>
<li>Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of Radiotherapy: New Paradigms. Radiat Res. 2014, Aug;182(2):123-5</li>
<li>Almo SC, Guha C. Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment. Radiat Res. 2014, Aug;182(2):230-8</li>
<li>Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. An Autologous In Situ Tumor Vaccination Approach for Hepatocellular Carcinoma. Flt3 Ligand Gene Transfer Increases Antitumor Effects of a Radio-Inducible Suicide Gene Therapy in an Ectopic Tumor Model. Radiat Res. 2014 Aug;182(2):201-10</li>
<li>Bernstein, Michael B; Garnett, Charlie T; Zhang, Huogang; Velcich, Anna; Wattenberg, Max M; Gameiro, Sofia R; Kalnicki, Shalom; Hodge, James W; Guha, Chandan. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer biotherapy & radiopharmaceuticals, 2014 May; 29 (4):153-61</li>
<li>Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res. 2013 Nov;1(5):280-4</li>
<li>Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013 Jul 24;8(7)</li>
<li>Zhang, Huagang; Liu, Laibin; Yu, Dong; Kandimalla, Ekambar R; Sun, Hui Bin; Agrawal, Sudhir; Guha, Chandan. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PloS one, 2012; 7 (5)</li>
<li>Hannan, Raquibul; Zhang, Huagang; Wallecha, Anu; Singh, Reshma; Liu, Laibin; Cohen, Patrice; Alfieri, Alan; Rothman, John; Guha, Chandan. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer immunology, immunotherapy: CII, 2012 Dec; 61 (12):2227-38</li>
</ol>
Stem cell based therapy for radiation injury
<ol>
<li>Benderitter, Marc; Caviggioli, Fabio; Chapel, Alain; Coppes, Robert P; Guha, Chandan; Klinger, Marco; Malard, Olivier; Stewart, Fiona; Tamarat, Radia; Luijk, Peter Van; Limoli, Charles L. Stem Cell Therapies for the Treatment of Radiation-Induced Normal Tissue Side Effects. Antioxidants & redox signaling, 2014, Jul 10;21(2):338-55</li>
<li>Zachman, Derek K; Leon, Ronald P; Das, Prerna; Goldman, Devorah C; Hamlin, Kimberly L; Guha, Chandan; Fleming, William H. Endothelial cells mitigate DNA damage and promote the regeneration of hematopoietic stem cells after radiation injury. Stem cell research, 2013 Nov; 11 (3):1013-21</li>
<li>Saha, Subhrajit; Bhanja, Payel; Liu, Laibin; Alfieri, Alan A; Yu, Dong; Kandimalla, Ekambar R; Agrawal, Sudhir; Guha, Chandan, ‘TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome’; PloS one, 2012; 7 (1)</li>
<li>Saha, Subhrajit; Bhanja, Payel; Kabarriti, Rafi; Liu, Laibin; Alfieri, Alan A; Guha, Chandan,. Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice. PloS one, 2011; 6 (9)</li>
<li>Bhanja P, Saha S, Kabarriti R, Liu L, Roy-Chowdhury N, Roy-Chowdhury J, Sellers RS, Alfieri AA, Guha C. Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. PLoS One. 2009 Nov 24;4(11)</li>
</ol>
Preparative irradiation to facilitate liver cell repopulation and stem cell engraftment in vivo
<ol>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics, 2014 Jul 15; 89 (4):786-803</li>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics. 2014 Jul 15; 89 (4):786-803</li>
<li>Yannam, Govardhana Rao; Han, Bing; Setoyama, Kentaro; Yamamoto, Toshiyuki; Ito, Ryotaro; Brooks, Jenna M; Guzman-Lepe, Jorge; Galambos, Csaba; Fong, Jason V; Deutsch, Melvin; Quader, Mubina A; Yamanouchi, Kosho; Kabarriti, Rafi; Mehta, Keyur; Soto-Gutierrez, Alejandro; Roy-Chowdhury, Jayanta; Locker, Joseph; Abe, Michio; Enke, Charles A; Baranowska-Kortylewicz, Janina; Solberg, Timothy D; Guha, Chandan; Fox, Ira J. A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury. International journal of radiation oncology, biology, physics, 2014 Feb 1; 88 (2):404-11</li>
<li>Miyazaki, Kensuke; Yamanouchi, Kosho; Sakai, Yusuke; Yamaguchi, Izumi; Takatsuki, Mitsuhisa; Kuroki, Tamotsu; Guha, Chandan; Eguchi, Susumu, ‘Construction of liver tissue inýývivo with preparative partial hepatic irradiation and growth stimulus: investigations of less invasive techniques and progenitor cells’; The Journal of surgical research. 2013 Dec; 185 (2):889-95</li>
<li>Puppi, Juliana; Strom, Stephen C; Hughes, Robin D; Bansal, Sanjay; Castell, Jose V; Dagher, Ibrahim; Ellis, Ewa C S; Nowak, Greg; Ericzon, Bo-Goran; Fox, Ira J; Gomez-Lechon, M Jose; Guha, Chandan; Gupta, Sanjeev; Mitry, Ragai R; Ohashi, Kazuo; Ott, Michael; Reid, Lola M; Roy-Chowdhury, Jayanta; Sokal, Etienne; Weber, Anne; Dhawan, Anil, ‘Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London’; Cell transplantation. 2012; 21 (1):1-10</li>
<li>Zhou, Hongchao; Dong, Xinyuan; Kabarriti, Rafi; Chen, Yong; Avsar, Yesim; Wang, Xia; Ding, Jianqiang; Liu, Laibin; Fox, Ira J; Roy-Chowdhury, Jayanta; Roy-Chowdhury, Namita; Guha, Chandan. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PloS one. 2012; 7 (10)</li>
<li>Ding, Jianqiang; Yannam, Govardhana R; Roy-Chowdhury, Namita; Hidvegi, Tunda; Basma, Hesham; Rennard, Stephen I; Wong, Ronald J; Avsar, Yesim; Guha, Chandan; Perlmutter, David H; Fox, Ira J; Roy-Chowdhury, Jayanta. Spontaneous hepatic repopulation in transgenic mice expressing mutant human ýý1-antitrypsin by wild-type donor hepatocytes. The Journal of clinical investigation, 2011 May; 121 (5):1930-4</li>
<li>Soltys, Kyle A; Soto-Gutierrez, Alejandro; Nagaya, Masaki; Baskin, Kevin M; Deutsch, Melvin; Ito, Ryotaro; Shneider, Benjamin L; Squires, Robert; Vockley, Jerry; Guha, Chandan; Roy-Chowdhury, Jayanta; Strom, Stephen C; Platt, Jeffrey L; Fox, Ira J. Barriers to the successful treatment of liver disease by hepatocyte transplantation. Journal of hepatology, 2010 Oct; 53 (4):769-74</li>
<li>Dawson, Laura A; Guha, Chandan. Hepatocellular carcinoma: radiation therapy. Cancer journal (Sudbury, Mass.), 2008 Mar-Apr; 14 (2):111-6</li>
<li>Agoni, Lorenzo; Basu, Indranil; Gupta, Seema; Alfieri, Alan; Gambino, Angela; Goldberg, Gary L; Reddy, E Premkumar; Guha, Chandan. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. International journal of radiation oncology, biology, physics, 2014 Apr 1; 88 (5):1180-7</li>
</ol>

EMR ID

4049

Is Open Scheduling

Off

Roy S. Chuck

Read more about Roy S. Chuck

Roy S. Chuck

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/99124b00-b3a6-11ee-8ab8-012a307002d3.jpg

Provider

Faculty

Expert

First Name

Roy

Last Name

Chuck

NPI

1447202338

Faculty ID

11721

CMO Specialties

Clinical Terms

Optical Coherence Tomography

Keratitis

Retinal Detachment Surgery

Drooping Eyelids

Bacterial Conjunctivitis

Retinal Vein Occlusion

Hyphema

Vision Screening

Color Blindness

Posterior Vitreous Detachment

Dry Eyes

Retinal Drusen

Dry Eye Syndrome

Chemical Conjunctivitis

Snow Blindness

Tonometry

Gonioscopy

Diabetic Retinopathy Screening

Retinal Artery Occlusion

Subconjunctival Hemorrhage

Allergic Conjunctivitis

Giant Papillary Conjunctivitis

Newborn Conjunctivitis

Scleral Buckling Surgery

Ectropion

Intraocular Pressure

Closed-Angle Glaucoma

Traction Retinal Detachment

Dacryocystitis

Nearsightedness

Keratoconus

Sturge-Weber Syndrome

Penetrating Eye Injury

Retinopathy Of Prematurity

Age-Related Macular Degeneration

Retinal Vascular Occlusion

Strabismus Surgery

Radial Keratotomy

Laser Trabeculoplasty

YAG Laser Capsulotomy

Employment Status

Full Time

Patient Type

Adult

Department

einstein-dept-ophthalmology-visual-sciences

einstein-dept-genetics

Gender

Male

rchuck@montefiore.org

Phone

718-920-2020

Titles

Type

Academic

Department

Department of Ophthalmology & Visual Sciences

Department Link

Rank

Professor

Type

Academic

Department

Department of Genetics

Department Link

Rank

Professor

Type

Clinical

Title

Chairman, Department of Ophthalmology & Visual Sciences

Type

Clinical

Title

Professor and Chairman, Paul Henkind Chair, Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine and Montefiore

Type

Administrative

Title

Chair, Department of Ophthalmology & Visual Sciences

Type

Administrative

Title

Paul Henkind Chair in Ophthalmology, Department of Ophthalmology & Visual Sciences

Locations

Is Primary

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.87862 40.88032)

Address Line 1

3400 Bainbridge Avenue

City

Bronx

State

Zip

10467-240

Location Title

Montefiore Greene Medical Arts Pavilion

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.85147 40.94383)

Address Line 1

1010 Central Park Avenue

City

Yonkers

State

Zip

10704-1044

Location Title

Montefiore Medical Group-Cross County

Is Primary

Off

Type

Clinical

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.87526 40.8725)

Address Line 1

3170 Webster Avenue

City

Bronx

State

Zip

10467

Location Title

Empire State Ambulatory Surgery Center

Is Primary

Off

Type

Academic

Location (Address, State, City, Zip)

Not used, will be deleted

Coordinates

POINT (-73.8785732 40.879979)

Address Line 1

Montefiore Medical Center

Address Line 2

Medical Arts Pavilion

Address Line 3

3400 Bainbridge Avenue

City

Bronx

State

Zip

10467

Location Title

Montefiore Medical Center

Education and Trainings

Education Type Label

Medical Education

Education Institution

Columbia Univ College of Physicians and Surgeons

Education Type Label

Fellowship

Education Institution

University of Southern California Medical Center

Education Type Label

Residency

Education Institution

Washington University School of Medicine

Professional Interests

Dr. Roy S. Chuck is an ophthalmologist, visual scientist and geneticist known for his stem cell and dry eye research, and work in corneal restoration. He chairs Einstein’s department of ophthalmology and visual sciences, one of only a handful of Asian-Americans to hold such a post in the U.S.
 
He also chairs the ophthalmology department at Montefiore Medical Center, overseeing tertiary care to adult and pediatric patients with diseases of the eye, with subspecialty expertise that includes neuro-ophthalmology, plastic surgery, and retina, cornea and glaucoma services. The department maintains a program of ongoing community outreach aimed at early detection and treatment of eye diseases.
 
Dr. Chuck is a cornea specialist with expertise in laser techniques for refractive eye conditions. He has deep research experience and holds multiple patents. His two main areas of research are corneal stem cell surgery and dry eye, the most common global eye disease. Recently, Dr. Chuck's team developed a unique mouse model of dry eye that allows animal testing of therapies. The model employs the use of botulinum toxin, commonly known as "botox," to block neurotransmitters in the tear-producing lacrimal gland. The resulting dry eye closely mimics that found in humans.
 
Dr. Chuck is a long-time stem cell investigator in connection with corneal transplantation and sight restoration. His work includes cutting-edge corneal stem cell surgery, which has a success rate of nearly 50-percent—one of the highest for stem cell surgery.  The operation is performed if the stem cell pool on the eye is wiped out through injury or a genetic condition. Without these regenerating cells, eye injuries, however small, result in opaque scars that reduce or even eliminate vision. Corneal stem cell surgery requires removing the scar tissue and transplanting donated corneal stem cells onto the eye. If successful, the introduced stem cells heal the wound and vision is restored.
 
At Einstein, Dr. Chuck is developing research centers focusing on ophthalmologic disorders including cataracts, ocular surface disease/dry eye, glaucoma, macular degeneration, and eye conditions associated with diabetes.

Research Areas

corneal spectroscopy
surgical device development
clinical trials

Specialties

Additional Specialties

Expert Tags

Eye Disease

Stem Cell Research

Areas of Expertise

Corneal disorders

Glaucoma

Refractive surgery

Stem Cell Research

Expert Summary

<div>Dr. Chuck is a prominent stem cell and dry eye researcher. He is a cornea specialist with expertise in the field of laser techniques, including LASIK surgery, corneal replacement, stem cell surgery, and refractive eye problems. </div>
<div> A basic scientist as well as a clinical researcher, Dr. Chuck has helped develop a unique model of dry eye using Botox that allows for testing of preclinical therapies. He has served as principal investigator on five FDA studies of vision correction and written more than 175 peer-reviewed papers and more than 100 book chapters and abstracts. Dr. Chuck has been featured several times on ABC News and ABC’s “Good Morning America” on various eye diseases and conditions. He serves on the editorial boards of several publications, including the Journal of Refractive Surgery and Lasers in Surgery and Medicine. </div>

Research Profile

https://einsteinmed.edu/faculty/11721/Roy-Chuck

Clinical Profile

https://montefioreeinstein.org/profiles/1447202338/roy-s-chuck

CHAM Provider

Off

Professional Title

M.D.

Ph.D.

Clinical Focus

Refractive surgery and corneal disorders including dry eye

Research Focus

Corneal reconstruction and stem cell surgery, dry eye, refractive surgery

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/6e0b5586-4346-4ff0-b417-cc144d59d…

EMR ID

5233

Biography

Roy S. Chuck, MD, PhD, is Chairman and Professor, Ophthalmology & Visual Sciences at Montefiore Einstein. Dr. Chuck’s clinical focus is in cornea and external diseases as well as refractive surgery.After earning his Bachelor of Science in engineering at University of California, Berkeley, in 1986, Dr. Chuck attended Columbia University, earning his Doctor of Medicine and Doctor of Philosophy in 1993. He started his postdoctoral training at St. Mary’s Health Center, completing a yearlong internship in internal medicine in 1994. From then until 1998, he pursued a residency in ophthalmology at Washington University and Barnes Hospital, acting as chief resident in his final year. In 1999, he completed a yearlong fellowship in cornea and refractive surgery at Doheny Eye Institute, University of Southern California.Dr. Chuck’s research has been published in numerous peer-reviewed journals as well as shared through many abstracts, book chapters and podium and poster presentations. He has been an editor and served on the editorial boards of many publications including the Lasers in Surgery and Medicine, Journal of Refractive Surgery, Current Opinion in Ophthalmology and BMC Ophthalmology. He currently serves as the Editor-in-Chief of the major journal ARVO Translational Vision Science and Technology and is a member of the NIH National Eye Institute Council of Editors.Dr. Chuck is board certified and is a member of many local, national and international professional societies including the International Society for Refractive Surgery, the American Society for Laser Medicine and Surgery, and the Manhattan Ophthalmological Society. He currently serves as Secretary for Quality of Care for the American Academy of Ophthalmology.

Is Open Scheduling

Off

Subscribe to Stem Cell Research